C42 Aptamer Details
ID# 8109
Structure
Chemistry
DNA
Target
Human PD1
Category
Cells
Affinity (Kd)
23 nM
Length
81
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-dGpdCpdTpdGpdTpdGpdTpdGpdApdCpdTpdCpdCpdTpdGpdCpdApdApdTpdGpdGpdTpdApdGpdCpdGpdGpdGpdTpdApdGpdGpdGpdGpdApdGpdGpdGpdApdGpdGpdGpdTpdGpdApdApdTpdGpdGpdApdGpdGpdApdTpdGpdTpdTpdCpdApdTpdGpdGpdCpdApdGpdCpdTpdGpdTpdApdTpdCpdTpdTpdGpdTpdCpdTpdCpdCp-3'
Molecular Weight: 25005.1
Extinction Coefficient: 772200
Binding Conditions / Buffer
5 ml of PBS-T containing 1 μg/ml bovine serum albumin (BSA) and 0.1 μg/ml tRNA
Binding Temp: 22°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Khedri M, Abnous K, Rafatpanah H, Nabavinia MS, Taghdisi SM, Ramezani M. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach. Immunol Invest. 2020 Jul;49(5):535-554. doi: 10.1080/08820139.2020.1744639. Epub 2020 May 19. PMID: 32429721.
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
